PLYX Stock Gets Stronger EPS Forecast from HC Wainwright

Polaryx Therapeutics, Inc. (NASDAQ:PLYX) – Equities researchers at HC Wainwright increased their Q3 2026 earnings estimates for Polaryx Therapeutics in a research note issued to investors on Tuesday, November 10th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.04) per share for the quarter, up from their previous estimate of ($0.06). The consensus estimate for Polaryx Therapeutics’ current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Polaryx Therapeutics’ Q4 2026 earnings at ($0.05) EPS, FY2026 earnings at ($0.18) EPS, Q1 2027 earnings at ($0.06) EPS, Q2 2027 earnings at ($0.06) EPS, Q3 2027 earnings at ($0.06) EPS, Q4 2027 earnings at ($0.06) EPS and FY2027 earnings at ($0.24) EPS.

Polaryx Therapeutics (NASDAQ:PLYX) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.02.

A number of other research analysts have also recently commented on the company. Wall Street Zen raised Polaryx Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th. Raymond James Financial began coverage on Polaryx Therapeutics in a research note on Thursday, August 13th. They set a “strong-buy” rating and a $6.00 price target for the company. Finally, Weiss Ratings upgraded Polaryx Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a report on Monday, November 2nd. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Polaryx Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.67.

Polaryx Therapeutics Stock Performance

Polaryx Therapeutics stock opened at $1.95 on Thursday. Polaryx Therapeutics has a fifty-two week low of $1.69 and a fifty-two week high of $48.91. The firm’s fifty day moving average price is $1.97 and its 200-day moving average price is $3.09.

About Polaryx Therapeutics

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.